Latest Headlines

  1. INTEGRA Helps To Streamline CRISPR Workflows, From Editing To Analysis 10/2/2026

    INTEGRA Biosciences has collaborated with biotechnology companies DropGenie and QUiCKR Bio to create efficient automated solutions for CRISPR editing and analysis.

  2. INTEGRA Biosciences Launches Its Most Sustainable ECO Racks Yet 10/2/2026

    INTEGRA Biosciences has introduced newly evolved ECO rack GRIPTIPS® pipette tips, which are now translucent rather than fully pigmented, making the recycled material more suitable for a wider range of new products.

  3. INTEGRA Launches New Eco-Friendly ACT Ecolabel Certified AUTO Rack GRIPTIPS® For Benchtop Systems 10/2/2026

    INTEGRA Biosciences has launched the My Green Lab® ACT® Ecolabel certified AUTO rack GRIPTIPS® pipette tips for its benchtop liquid handling platforms.

  4. DaltonTx, The Decision Engine For Drug Discovery, Launches Advanced AI-Powered Antibody Discovery Platform 10/1/2026

    DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform.

  5. Talus Bio Launches Ptarmigan-1, The First Structure-Free AI Model For Proteome-Wide Drug Discovery 10/1/2026

    Talus Bioscience, Inc. (“Talus Bio”), an AI-native therapeutics company, today released Ptarmigan-1, the first structure-free model that can accurately predict small molecule binding sites across the entire human proteome, including proteins too disordered for traditional 3D modeling to resolve.

  6. Rakovina Therapeutics Partners With Boston-Based Celvion Therapeutics To Leverage AI And Real-World Clinical Data For Precision Cancer Drug Development 10/1/2026

    Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EMphora™ artificial intelligence platform to identify novel precision medicine strategies designed to accelerate the development of Rakovina’s ATR inhibitor program.

  7. Piramal Pharma Solutions And NP2 To Complete Cyclophosphamide Development Phase Next Month 9/30/2026

    Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.

  8. Breaking The Safety Barrier: Insilico Medicine Nominates ISM1354, The Next-Generation Small Molecule GIPR Antagonist 9/30/2026

    As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth.

  9. FDA Accepts New Drug Application For CeleCor's Investigational Heart-Attack Drug 9/30/2026

    The U.S. Food and Drug Administration has accepted CeleCor Therapeutics' New Drug Application (NDA) for zalunfiban (DisaggproTM) and assigned a target action date of June 18, 2027 under the Prescription Drug User Fee Act (PDUFA).

  10. Tremont AI Emerges From Stealth To Bring Multimodal AI To Preclinical Drug Safety 9/29/2026

    Tremont AI, a biomedical AI company focused on preclinical drug safety, today emerged from stealth. The company is developing multimodal foundation models and AI agents to help scientists analyze and interpret evidence across preclinical safety studies.